Multiple Dosing of Mesenchymal Stromal Cells in Patients With ARDS (COVID-19)

NCT04466098 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

8

Enrollment

OTHER

Sponsor class

Conditions

Acute Respiratory Distress Syndrome
ARDS (Moderate or Severe)
COVID-19 Pneumonia

Interventions

BIOLOGICAL: Mesenchymal stromal cells
OTHER: Placebo

Sponsor

Masonic Cancer Center, University of Minnesota